Founded in 2020, Taysha Gene Therapies is a public biotechnology company in Dallas, Texas, focused on developing curative medicines for monogenic CNS diseases. By combining its experience in gene therapy drug development and commercialization with UT Southwestern’s Gene Therapy Program, Taysha has built an extensive targeted pipeline focused on both rare and large-market indications. This alliance allows Taysha to rapidly translate treatments from early discovery into the clinics to treat patients with progressive neurological disease. The company announced pricing of its Initial Public Offering on NASDAQ in September 2020, just five months after receiving initial funding. Find out more about Taysha’s IPO.